Metagenomic Next-Generation Sequencing for Pulmonary Fungal Infection Diagnosis: Lung Biopsy versus Bronchoalveolar Lavage Fluid
Lei Yang,Junxiu Song,Yubao Wang,Jing Feng
DOI: https://doi.org/10.2147/IDR.S333818
2021-10-21
Infection and Drug Resistance
Abstract:Lei Yang, 1 Junxiu Song, 1 Yubao Wang, 2 Jing Feng 1 1 Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, People's Republic of China; 2 Institute of Infectious Diseases, The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China Correspondence: Yubao Wang Institute of Infectious Diseases, The Second Hospital of Tianjin Medical University, Pingjiang Road NO. 23, Tianjin, 300211, People's Republic of China Email Jing Feng Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Anshan Road No. 154, Heping District, Tianjin, 300052, People's Republic of China Email Purpose: Metagenomic next-generation sequencing (mNGS) is widely used for pulmonary infection; nonetheless, the experience from its clinical use in diagnosing pulmonary fungal infections is sparse. This study aimed to compare mNGS results from lung biopsy and bronchoalveolar lavage fluid (BALF) and determine their clinical diagnostic efficacy. Patients and Methods: A total of 106 patients with suspected pulmonary fungal infection from May 2018 to January 2020 were included in this retrospective study. All patients' lung biopsy and BALF specimens were collected through bronchoscopy. Overall, 45 (42.5%) patients had pulmonary fungal infection. The performance of lung biopsy and BALF used for mNGS in diagnosing pulmonary fungal infections and identifying pathogens was compared. Additionally, mNGS was compared with conventional tests (pathology, galactomannan test, and cultures) with respect to the diagnosis of pulmonary fungal infections. Results: Lung biopsy-mNGS and BALF-mNGS exhibited no difference in terms of sensitivity (80.0% vs 84.4%, P =0.754) and specificity (91.8% vs 85.3%, P =0.39). Additionally, there was no difference in specificity between mNGS and conventional tests; however, the sensitivity of mNGS (lung biopsy, BALF) in diagnosing pulmonary fungal infections was significantly higher than that of conventional tests (conventional tests vs biopsy-mNGS: 44.4% vs 80.0%, P < 0.05; conventional tests vs BALF-mNGS: 44.4% vs 84.4%, P < 0.05). Among 32 patients with positive mNGS results for both biopsy and BALF specimens, 23 (71.9%) cases of consistency between the two tests for the detected fungi and nine (28.1%) cases of a partial match were identified. Receiver operating curve analysis revealed that the area under the curve for the combination of biopsy and BALF was significantly higher than that for BALF-mNGS ( P =0.018). Conclusion: We recommend biopsy-based or BALF-based mNGS for diagnosing pulmonary fungal infections because of their diagnostic advantages over conventional tests. The combination of biopsy and BALF for mNGS can be considered when higher diagnostic efficacy is required. Keywords: mNGS, diagnosis, sensitivity, specificity In recent years, with the increase in high-risk groups requiring immunosuppressant use, the prevalence of pulmonary fungal disease has shown a significant upward trend. The main sources of fungal infections in human lungs are opportunistic fungi: Aspergillus, Cryptococcus, Pneumocystis jirovecii , and endemic fungi. Among them, Aspergillus and Cryptococcus are the main fungal pathogens associated with lung infections. 1 Microscopic smears and cultures are conventional microbial methods used for pathogen identification; however, both methods are time consuming and not highly sensitive. The gold standard for the detection of invasive fungal infections is histopathological diagnosis. However, it is time consuming, it cannot identify pathogens, and it has low sensitivity. For Aspergillus infections, the positive predictive value (PPV) of respiratory specimen cultures obtained by sputum induction or bronchoalveolar lavage fluid (BALF) is low (approximately 72%). 2 When testing patients with non-hematological diseases or those who have been treated with antifungal drugs, the PPV may be even lower. 3 Clinically, BALF's galactomannan (GM) test results are affected by various factors, which can lower the sensitivity and increase the false positivity rate. 4–7 Since the conventional tests for the diagnosis of pulmonary fungal infections have a low sensitivity and are influenced by various factors, there is an urgent need for new technology with a higher sensitivity for the diagnosis of pulmonary fungal infections. Currently, metagenomic next-generation sequencing (mNGS) is a widely used method for the clinical detection of pathogens and has obvious advantages in pathogen detection. 8 One study show -Abstract Truncated-
pharmacology & pharmacy,infectious diseases